Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
42 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | active not recruiting | Phase 2 | 189 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Aug 21, 2026 | clinicaltrials |
| NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.(ADAPTATION) | not yet recruiting | Phase 2 | 50 | Odense University HospitalOTHER |
| 4 |
| Aug 11, 2026 |
| clinicaltrials |
| NCT04895722 | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). | active not recruiting | Phase 2 | 302 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 2, 2026 | clinicaltrials |
| NCT05144841 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | completed | Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 28, 2026 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT03041311 | Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC | completed | Phase 2 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT04191616 | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet(SELECT) | completed | Phase 2 | 54 | AmgenINDUSTRY | 8 | Sep 4, 2025 | clinicaltrials |
| NCT04607850 | Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions | completed | Phase 1 / Phase 2 | 108 | Barinthus BiotherapeuticsINDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | completed | Phase 2 | 154 | Incyte CorporationINDUSTRY | 18 | Aug 22, 2025 | clinicaltrials |
| NCT02205047 | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma(INNOVATION) | completed | Phase 2 | 172 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 31, 2025 | clinicaltrials |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | completed | Phase 1 / Phase 2 | 211 | Agenus Inc.INDUSTRY | 9 | Jul 30, 2025 | clinicaltrials |
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients(SABLe) | active not recruiting | Phase 2 | 50 | Ida Bruun KristensenOTHER | 3 | Mar 18, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | completed | Phase 1 / Phase 2 | 1,080 | GlaxoSmithKlineINDUSTRY | 8 | Feb 3, 2025 | clinicaltrials |
| NCT02825628 | Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)(CRPC) | completed | Phase 2 | 55 | DexTech Medical ABINDUSTRY | 4 | Aug 29, 2024 | clinicaltrials |
| NCT03267316 | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors(CANFOUR) | completed | Phase 1 / Phase 2 | 167 | Cantargia ABINDUSTRY | 11 | Aug 22, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT03267030 | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | completed | Phase 2 | 55 | Birgitte Klug AlbertsenOTHER | 6 | Mar 15, 2024 | clinicaltrials |
| NCT04392505 | Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study(DART) | active not recruiting | Phase 2 | 100 | Oslo University HospitalOTHER | 4 | Feb 29, 2024 | clinicaltrials |
| NCT03003520 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 46 | CelgeneINDUSTRY | 5 | May 22, 2023 | clinicaltrials |
| NCT03130790 | Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) | completed | Phase 2 / Phase 3 | 52 | ASLAN PharmaceuticalsOTHER | 8 | Feb 15, 2022 | clinicaltrials |
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | completed | Phase 2 | 60 | Grifols Therapeutics LLCINDUSTRY | 10 | Mar 30, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | completed | Phase 2 | 62 | Grifols Therapeutics LLCINDUSTRY | 10 | Mar 5, 2019 | clinicaltrials |
| NCT01304524 | A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3(HPV-003) | completed | Phase 2 | 167 | Inovio PharmaceuticalsINDUSTRY | 9 | Sep 7, 2018 | clinicaltrials |
| NCT01860638 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | completed | Phase 2 | 296 | Hoffmann-La RocheINDUSTRY | 15 | Apr 30, 2018 | clinicaltrials |
| NCT02596243 | Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) | unknown | Phase 2 | 134 | Genexine, Inc.INDUSTRY | 3 | Jul 12, 2017 | clinicaltrials |
| NCT01317641 | Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 136 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Mar 29, 2017 | clinicaltrials |
| NCT01429064 | Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 | completed | Phase 2 | 76 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Feb 20, 2017 | clinicaltrials |
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT01374425 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)(MAVERICC) | completed | Phase 2 | 376 | Genentech, Inc.INDUSTRY | 7 | Aug 11, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT00444587 | A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. | completed | Phase 2 | 114 | Hoffmann-La RocheINDUSTRY | 8 | Jun 21, 2016 | clinicaltrials |
| NCT00479752 | Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer(CORE 2) | completed | Phase 2 | 151 | Central European Cooperative Oncology GroupOTHER | 13 | Feb 18, 2016 | clinicaltrials |
| NCT00796757 | A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC). | completed | Phase 2 | 146 | Hoffmann-La RocheINDUSTRY | 12 | May 27, 2015 | clinicaltrials |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | completed | Phase 2 | 228 | GlaxoSmithKlineINDUSTRY | 13 | May 8, 2015 | clinicaltrials |
| NCT00558363 | ARTS - AVODART After Radical Therapy For Prostate Cancer Study(ARTS) | completed | Phase 2 | 294 | GlaxoSmithKlineINDUSTRY | 9 | Mar 21, 2012 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
| NCT00636740 | Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients | completed | Phase 2 | 30 | Merrion Pharmaceuticals, LLCINDUSTRY | 3 | Feb 20, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials